ArticleBMC cancer2018

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.

Rui-Lian Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.